Atossa Therapeutics Inc (NASDAQ: ATOS) on Friday, plunged -3.17% from the previous trading day, before settling in for the closing price of $0.87. Within the past 52 weeks, ATOS’s price has moved between $0.55 and $1.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 36.92% over the past five years. The company achieved an average annual earnings per share of -16.25%. With a float of $129.12 million, this company’s outstanding shares have now reached $129.17 million.
Let’s look at the performance matrix of the company that is accounted for 15 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Atossa Therapeutics Inc (ATOS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atossa Therapeutics Inc is 0.04%, while institutional ownership is 26.48%. The most recent insider transaction that took place on May 21 ’25, was worth 9,887. In this transaction President & CEO of this company bought 11,239 shares at a rate of $0.88, taking the stock ownership to the 13,898 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 10,000 for $0.70, making the entire transaction worth $7,000. This insider now owns 10,257 shares in total.
Atossa Therapeutics Inc (ATOS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -16.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.47% during the next five years compared to 36.92% growth over the previous five years of trading.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Atossa Therapeutics Inc (ATOS) is currently performing well based on its current performance indicators. A quick ratio of 12.67 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Atossa Therapeutics Inc (NASDAQ: ATOS) saw its 5-day average volume 0.66 million, a negative change from its year-to-date volume of 0.81 million. As of the previous 9 days, the stock’s Stochastic %D was 28.25%.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 55.91%, which indicates a significant increase from 19.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0540 in the past 14 days, which was lower than the 0.0554 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8651, while its 200-day Moving Average is $0.9709. Nevertheless, the first resistance level for the watch stands at $0.8750 in the near term. At $0.9081, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9262. If the price goes on to break the first support level at $0.8238, it is likely to go to the next support level at $0.8057. The third support level lies at $0.7726 if the price breaches the second support level.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
Market capitalization of the company is 108.75 million based on 129,170K outstanding shares. Right now, sales total 0 K and income totals -25,500 K. The company made 0 K in profit during its latest quarter, and -6,720 K in sales during its previous quarter.
